In contrast, Goulielmaki and colleagues found that a high density of HER-2/neu(780–788)-specific CD8+ T cells in the peripheral blood of PCa patients undergoing conventional treatment was associated with better progression-free survival (PFS) compared to patients with a low density of the cells [88]. The gene discussed is CD8A; the disease is posterior cortical atrophy.